Dr Kyriakopoulos on the Investigation of Masofaniten Plus Enzalutamide in mCRPC

Dr Kyriakopoulos sheds light on the potential synergy and pharmacokinetic interactions between masofaniten and enzalutamide when used in combination for patients with prostate cancer; contextualizes safety and pharmacokinetic findings from the phase 1 portion of a phase 1/2 study; and outlines key objectives of the agent’s ongoing evaluation in the phase 2 portion of the study.